MicroTech Medical (Hangzhou) Co., Ltd. Class H (HK:2235)
:2235
Top Page
MicroTech Medical (Hangzhou) Co., Ltd. Class H
(2235)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$7.50
▲(5.63% Upside)
Action:ReiteratedDate:11/01/25
MicroTech Medical's overall stock score is primarily impacted by its financial performance, marked by strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates bearish momentum, and valuation metrics are weak due to a negative P/E ratio. The absence of earnings call data and corporate events leaves these areas unaddressed.
Positive Factors
Revenue Growth
Sustained top-line growth demonstrates expanding adoption of its diabetes devices and recurring consumables. Continued revenue momentum supports scale, enabling investment in R&D, distribution and commercialization that can drive durable improvements in unit economics over the medium term.
Negative Factors
Negative Net Profit Margin
An -18% net margin shows the company remains loss-making after operating and non-operating items, signaling structural profitability gaps. Without meaningful cost reductions, pricing power or higher-volume leverage, losses are likely to persist and constrain retained earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line growth demonstrates expanding adoption of its diabetes devices and recurring consumables. Continued revenue momentum supports scale, enabling investment in R&D, distribution and commercialization that can drive durable improvements in unit economics over the medium term.
Read all positive factors
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.12B
Dividend YieldN/A
Average Volume (3M)340.61K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth49.86%
EPS Growth80.35%
CountryHK
Employees678
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.11
Shares Outstanding169,175,840
10 Day Avg. Volume114,320
30 Day Avg. Volume340,611
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)1.22
Price to Sales (P/S)6.98
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$14.00Price Target Upside97.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$895.20M
MicroTech Medical (Hangzhou) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables in the People's Republic of China and internationally. Its products include E...
How the Company Makes Money
MicroTech Medical generates revenue primarily through the sale of its medical devices and technology solutions. Key revenue streams include direct sales of insulin delivery systems, blood glucose monitoring devices, and related accessories to hosp...
MicroTech Medical (Hangzhou) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 317.77M | 345.62M | 248.35M | 173.54M | 151.40M | 75.28M |
| Gross Profit | 162.57M | 182.85M | 123.22M | 79.66M | 70.88M | 36.54M |
| EBITDA | -62.16M | -121.38M | -184.12M | -110.19M | -39.80M | -141.52M |
| Net Income | -26.53M | -63.12M | -125.02M | -35.04M | -48.18M | -121.01M |
Balance Sheet | ||||||
| Total Assets | 2.21B | 2.15B | 2.16B | 2.29B | 2.33B | 777.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.72B | 1.71B | 1.89B | 2.05B | 2.15B | 654.99M |
| Total Debt | 30.83M | 4.20M | 5.06M | 717.00K | 255.00K | 126.00K |
| Total Liabilities | 238.37M | 171.72M | 97.70M | 82.06M | 82.48M | 48.76M |
| Stockholders Equity | 1.97B | 1.97B | 2.06B | 2.21B | 2.25B | 728.52M |
Cash Flow | ||||||
| Free Cash Flow | 118.45M | -203.88M | -181.69M | -137.45M | -62.94M | -35.26M |
| Operating Cash Flow | 76.64M | -120.65M | -153.00M | -107.67M | -44.22M | -9.57M |
| Investing Cash Flow | -41.22M | 121.16M | -540.70M | -965.58M | 97.69M | -1.22M |
| Financing Cash Flow | -19.35M | -33.15M | -23.46M | -20.57M | 1.57B | 511.28M |
MicroTech Medical (Hangzhou) Co., Ltd. Class H Technical Analysis
Positive
7.10
Price Trends
7.33
Positive
7.28
Positive
7.23
Positive
Market Momentum
-0.04
Negative
55.22
Neutral
98.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2235, the sentiment is Positive. The current price of 7.1 is below the 20-day moving average (MA) of 7.19, below the 50-day MA of 7.33, and below the 200-day MA of 7.23, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 55.22 is Neutral, neither overbought nor oversold. The STOCH value of 98.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2235.
MicroTech Medical (Hangzhou) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$6.32B | 31.02 | 11.84% | 1.50% | -5.18% | -9.69% | |
53 Neutral | HK$965.82M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$3.12B | -495.98 | -1.35% | ― | 49.86% | 80.35% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.40
1.48
25.00%
DE:4WO
Peijia Medical Ltd.
0.66
0.16
32.00%
DE:7W3
Acotec Scientific Holdings Limited
1.40
0.70
98.58%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2172
MicroPort NeuroTech Limited
10.81
1.72
18.92%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.19
0.38
20.99%
MicroTech Medical (Hangzhou) Co., Ltd. Class H Corporate Events
MicroTech Medical Grants 3.3 Million Incentive Shares to Directors and Key Staff
Dec 30, 2025
MicroTech Medical (Hangzhou) Co., Ltd. has granted a total of 3.3 million H shares, representing about 0.79% of its issued share capital (excluding treasury shares), to 51 eligible participants under a newly adopted share incentive scheme. The gra...
MicroTech Medical Shareholders Approve New Share Incentive Scheme at 2025 EGM
Dec 24, 2025
MicroTech Medical (Hangzhou) Co., Ltd. held its first extraordinary general meeting of 2025 in Hangzhou, where all resolutions put to shareholders were approved by poll. With 71.29% of voting shares represented, shareholders backed both the adopti...
MicroTech Medical Wins Brazil Approval for LinX Glucose Monitoring System
Dec 23, 2025
MicroTech Medical (Hangzhou) Co., Ltd. announced that its LinX continuous glucose monitoring system, the international brand name of AiDEX X, has received market approval in Brazil for use in both adults and children. Given Brazil’s status a...
MicroTech Medical Announces 2025 EGM to Discuss Share Incentive Scheme
Dec 5, 2025
MicroTech Medical (Hangzhou) Co., Ltd. has announced its 2025 first extraordinary general meeting (EGM) to be held on December 24, 2025. The meeting will address resolutions concerning the approval of a Share Incentive Scheme, which could impact t...
MicroTech Medical’s LinX System Gains Approval in India, Expanding Global Reach
Nov 26, 2025
MicroTech Medical has announced that its continuous glucose monitoring system, LinX, has received market approval in India, a strategically important and high-growth market. This approval is expected to significantly enhance the company’s in...
MicroTech Medical Announces Changes in Proceeds Utilization and Timetable Extension
Nov 17, 2025
MicroTech Medical (Hangzhou) Co., Ltd. has announced a change in the utilization of its remaining unutilized proceeds from its Global Offering and an extension of the expected timetable for their use. The company plans to fully utilize the funds b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.